Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

United Cannabis Corporation: The Intersection of Cannabis and BioPharma

Statement Issued Following the Administration's Recent Comments

DENVER, CO / ACCESSWIRE / March 15, 2017 / United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United Cannabis") today issued a statement regarding the Company's operation:

United Cannabis Corporation is a biotech company dedicated to the development of whole-plant, phytocannabinoid-based applications, formulations, and technologies for the pharmaceutical, medical cannabis, and hemp markets.

Earnest Blackmon, Chief Executive Officer of United Cannabis, explained the statement, saying, "Recent comments by officials in the new administration indicate a potential shift in the federal position on marijuana from that of the Obama administration, and we felt it necessary to assure our shareholders and the public markets that our operations focus solely on medical cannabis, which is now legal in 28 states across the country."

Tony Verzura, the Company's Chief Technology Officer, added, "Our focus has always been to develop naturopathic technology, methods of use, and other IP to be used in the medical cannabis, hemp, and pharmaceutical industries, and we have seen profound improvements in the lives of patients that utilize our patent-pending Prana Medicinal products."

About United Cannabis Corporation

The Company's Prana Bio Medicinal products provide patients a way to mix/match cannabinoids for therapeutic purpose. These products, licensed to regulated marijuana dispensaries, are broken into 5 categories that are available in capsules, sublingual's, and topical delivery methods. The Company uses a patent-pending infusion process utilizing select fatty acids, lipids, and specific combination of cannabis derived terpenes to increase bioavailability.

For further information, please visit www.unitedcannabis.us.

Contact: Staff@UnitedCannabis.us

Phone: 303-386-7321

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors, created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

SOURCE: United Cannabis Corporation

Tags:


USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse